Reliability and Extension of Quantitative Prediction of CYP3A4-Mediated Drug Interactions Based on Clinical Data

Botanical Review

Volumn 16, Issue 6, 2014, Pages 1309-1320

  Loue, Constance ^a   Tod, Michel ^a,b  

^a CROIX ROUSSE HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

CYP3A4; drug interaction; inhibition; pharmacokinetics; prediction

Indexed keywords

CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; CYTOCHROME P450 3A INHIBITOR; DRUG; ALPRAZOLAM; AMITRIPTYLINE; ATORVASTATIN; BOCEPREVIR; BUSPIRONE; CERIVASTATIN; CLARITHROMYCIN; COLCHICINE; CYCLOSPORIN; CYTOCHROME P450 3A4 INHIBITOR; CYTOCHROME P450 INHIBITOR; DRONEDARONE; EPLERENONE; FELODIPINE; GEFITINIB; IMATINIB; KETOCONAZOLE; MEFLOQUINE; METHYLPREDNISOLONE; MEVINOLIN; MIDAZOLAM; NIFEDIPINE; NISOLDIPINE; PREDNISOLONE; QUETIAPINE; QUINIDINE; RILPIVIRINE; RIVAROXABAN; TRIAZOLAM; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AREA UNDER THE CURVE; BEVERAGE; BIOLOGICAL MODEL; BLOOD; CITRUS; DRUG INTERACTION; ENZYME SPECIFICITY; FOOD DRUG INTERACTION; HUMAN; METABOLISM; PREDICTIVE VALUE; REGRESSION ANALYSIS; ANALYTICAL ERROR; ARTICLE; CONTRIBUTION RATIO; DRUG CLEARANCE; DRUG POTENCY; DRUG POTENTIATION; ENZYME SUBSTRATE; GRAPEFRUIT JUICE; IN VIVO STUDY; INHIBITION RATIO; MATHEMATICAL ANALYSIS; PHARMACOLOGICAL PARAMETERS; PREDICTION; RELIABILITY;

AREA UNDER CURVE; BEVERAGES; CITRUS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 CYP3A INHIBITORS; DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; SUBSTRATE SPECIFICITY;

EID: 84938799031     PISSN: 00068101     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-014-9663-y     Document Type: Article

References (50)

1. Zhou S-F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008;9(4):310–22.
2. Examples of sensitive in vivo CYP substrates and CYP substrates with narrow therapeutic range (7/28/2011) [Internet]. Available from http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#classSub. Accessed 29 Jul 2014
3. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38(1):41–57.
4. Zhou S-F, Xue CC, Yu X-Q, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29(6):687–710.
5. Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet. 2007;46(8):681–96.
6. Ohno Y, Hisaka A, Ueno M, Suzuki H. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet. 2008;47(10):669–80.
7. Tod M, Goutelle S, Clavel-Grabit F, Nicolas G, Charpiat B. Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions. Clin Pharmacokinet. 2011;50(8):519–30.
8. Castellan A-C, Tod M, Gueyffier F, Audars M, Cambriels F, Kassaï B, et al. Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure. Clin Pharmacokinet. 2013;52(3):199–209.
9. Goutelle S, Bourguignon L, Bleyzac N, Berry J, Clavel-Grabit F, Tod M. In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates. AAPS J. 2013;15(2):415–26.
10. Tod M, Nkoud-Mongo C, Gueyffier F. Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach. AAPS J. 2013;15(4):1242–52.
11. Kenworthy KE, Bloomer JC, Clarke SE, Houston JB. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol. 1999;48(5):716–27.
12. Kenworthy KE, Clarke SE, Andrews J, Houston JB. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos Biol Fate Chem. 2001;29(12):1644–51.
13. Galetin A, Clarke SE, Houston JB. Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. Drug Metab Dispos Biol Fate Chem. 2003;31(9):1108–16.
14. Foti RS, Rock DA, Wienkers LC, Wahlstrom JL. Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos. 2010;38(6):981–7.
15. Congdon PP. Bayesian statistical modelling. John Wiley & Sons; 2007. 598 p.
16. Ntzoufras I. Bayesian modeling using WinBUGS. John Wiley & Sons; 2011. 422 p.
17. Guest EJ, Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT, Houston JB, Galetin A. Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. Br J Clin Pharmacol. 2011;71(1):72–87.
18. Lefèvre G, Carpenter P, Souppart C, Schmidli H, McClean M, Stypinski D. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. Br J Clin Pharmacol. 2002;54(5):485–92.
19. Bailey DG, Malcolm J, Arnold O, David SJ. Grapefruit juice-drug interactions. Br J Clin Pharmacol. 1998;46(2):101–10.
20. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther. 2006;316(1):336–48.
21. Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, Unadkat JD. Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. Drug Metab Dispos Biol Fate Chem. 2011;39(6):1070–8.
22. Kirby BJ, Collier AC, Kharasch ED, Dixit V, Desai P, Whittington D, et al. Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir. Drug Metab Dispos Biol Fate Chem. 2011;39(12):2329–37.
23. Liu P, Foster G, Gandelman K, LaBadie RR, Allison MJ, Gutierrez MJ, et al. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother. 2007;51(10):3617–26.
24. Imazio M, Brucato A, Trinchero R, Spodick D, Adler Y. Colchicine for pericarditis: hype or hope? Eur Heart J. 2009;30(5):532–9.
25. Kasserra C, Hughes E, Treitel M, et al. Clinical pharmacology of boceprevir: metabolism, excretion, and drug-drug interactions [abstract 118 ]. 18th Conference on Retroviruses and Opportunistic Infections Boston, USA; 2011.
26. Clarithromycine-Oct2010.pdf [Internet]. [cited 2013 May 17]. Available from: http://db.cbg-meb.nl/veegactie/csp/Clarithromycine-Oct2010.pdf
27. Invirase, INN-saquinavir mesilate-WC500035084.pdf [Internet]. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000113/WC500035084.pdf. Accessed 17 May 2013
28. Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63(8):2226–37.
29. Multaq, INN-dronedarone-WC500044534.pdf [Internet]. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001043/WC500044534.pdf. Accessed 17 May 2013
30. Ragueneau-Majlessi I, Boulenc X, Rauch C, Hachad H, Levy RH. Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis. Curr Drug Metab. 2007;8(8):810–4.
31. Incivo, INN-telaprevir-WC500115529.pdf [Internet]. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002313/WC500115529.pdf. Accessed 17 May 2013
32. Varis T, Backman JT, Kivistö KT, Neuvonen PJ. Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. Clin Pharmacol Ther. 2000;67(3):215–21.
33. Laganière S, Davies RF, Carignan G, Foris K, Goernert L, Carrier K, et al. Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. Clin Pharmacol Ther. 1996;60(3):255–64.
34. Edurant, INN-rilpivirine-WC500118874.pdf [Internet]. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002264/WC500118874.pdf. Accessed 10 Jul 2013
35. Xarelto, INN-rivaroxaban-WC500057108.pdf [Internet]. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. Accessed 29 May 2013
36. Muirhead GJ, Faulkner S, Harness JA, Taubel J. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. Br J Clin Pharmacol. 2002;53 Suppl 1:37S–43S.
37. Rapamune, INN-sirolimus-WC500046437.pdf [Internet]. Available from http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000273/WC500046437.pdf. Accessed 17 May 2013
38. CIALIS, INN-Tadalafil-WC500026318.pdf [Internet]. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000436/WC500026318.pdf. Accessed 17 May 2013
39. Brilique,INN-ticagrelor-WC500100494.pdf [Internet]. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001241/WC500100494.pdf. Accessed 17 May 2013
40. Victrelis, INN-boceprevir-WC500109786.pdf [Internet]. Available from http://www.ema.europa.eu/docs/fr_FR/document_library/EPAR_-_Product_Information/human/002332/WC500109786.pdf. Accessed 17 May 2013
41. Krishna G, Ma L, Prasad P, Moton A, Martinho M, O’Mara E. Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers. Expert Opin Drug Metab Toxicol. 2012;8(1):1–10.
42. Norvir, INN-ritonavir-WC500028728.pdf [Internet]. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000127/WC500028728.pdf. Accessed 29 May 2013
43. Merck & Co Inc. Victrelis prescribing information [Internet]. 2012. Available from http://www.hep-druginteractions.org. Accessed 10 Jul 2013
44. Wilby KJ, Greanya ED, Ford J-AE, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol. 2012;11(2):179–85.
45. CROI 2011 Paper #118 [Internet]. Available from http://www.retroconference.org/2011/Abstracts/41140.htm. Accessed 29 May 2013
46. Lebrun-Vignes B, Archer VC, Diquet B, Levron JC, Chosidow O, Puech AJ, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol. 2001;51(5):443–50.
47. Glynn AM, Slaughter RL, Brass C, D’Ambrosio R, Jusko WJ. Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. Clin Pharmacol Ther. 1986;39(6):654–9.
48. Damkier P, Hansen LL, Brøsen K. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol. 1999;48(6):829–38.
49. Edwards DJ, Lavoie R, Beckman H, Blevins R, Rubenfire M. The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine. Clin Pharmacol Ther. 1987;41(1):68–73.
50. Noxafil, INN-posaconazole-WC500037784.pdf [Internet]. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000610/WC500037784.pdf. Accessed 10 Jul 2013